FindTrial
Sign In

Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppression in the treatment of hepatitis-related aplastic anemia: a single-center cohort study

Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppressive therapy in patients with hepatitis-related aplastic anemia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050948
Enrollment
Unknown
Registered
2021-09-08
Start date
2021-09-10
Completion date
Unknown
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis-associated Aplastic Anemia

Interventions

ematopoietic stem cell transplantation group:Nil
ATG combined with cyclosporine group :Nil

Sponsors

Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with hepatitis-related aplastic anemia, hepatitis-related aplastic anemia is aplastic anemia that occurs within 6 months after the onset of acute hepatitis; 2. Those who have participated in or are participating in other clinical trials within the past three months.

Exclusion criteria

Exclusion criteria: 1. Paroxysmal nocturnal hemoglobinuria (PNH) clone with obvious clinical or biochemical evidence of hemolysis; 2. Unable to receive IST or HSCT treatment due to concurrent dysfunction of other systems or organs.

Design outcomes

Primary

MeasureTime frame
efficacy;blood routine;bone marrow smear;lymphocyte subsets;safety;—

Secondary

MeasureTime frame
ferritins;—

Countries

China

Contacts

Public ContactWu Dijiong

Zhejiang Provincial Hospital of Traditional Chinese Medicine

wdj850@163.com+86 571 86620325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026